Showing results (1-10 of 14) with videos related to
Sort By:
Pageof 2
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|August 8, 2014
Cushing disease: highlighting the importance of early diagnosis for both de novo and recurrent disease in light of evolving treatment patternsElizabeth M Lamos, Kashif M MunirCase Reports in Endocrinology|March 5, 2016
Thyroid Swelling and Thyroiditis in the Setting of Recent hCG Injections and Fine Needle AspirationElizabeth M Lamos, Kashif M MunirExpert Opinion on Drug Metabolism & Toxicology|February 20, 2014
Vildagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetesStephanie A Stein, Elizabeth M Lamos, Stephen N DavisExpert Opinion on Drug Safety|June 9, 2016
Cardiovascular effects of anti-diabetes drugsLisa M Younk, Elizabeth M Lamos, Stephen N DavisExpert Opinion on Drug Metabolism & Toxicology|April 18, 2013
Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitusElizabeth M Lamos, Lisa M Younk, Stephen N DavisTherapeutics and Clinical Risk Management|March 30, 2016
Concentrated insulins: the new basal insulinsElizabeth M Lamos, Lisa M Younk, Stephen N DavisExpert Opinion on Investigational Drugs|April 22, 2014
Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetesElizabeth M Lamos, Lisa M Younk, Stephen N DavisExpert Opinion on Drug Safety|June 6, 2014
The cardiovascular effects of insulinLisa M Younk, Elizabeth M Lamos, Stephen N DavisExpert Review of Clinical Pharmacology|April 22, 2021
Effects of anti-diabetic treatments in type 2 diabetes and fatty liver diseaseElizabeth M Lamos, Megan Kristan, Maka Siamashvili, et al.Expert Opinion on Pharmacotherapy|November 10, 2018
Pharmacoeconomic evaluation of sodium-glucose transporter-2 (SGLT2) inhibitors for the treatment of type 2 diabetesWedad Rahman, Paul Joseph Solinsky, Kashif M Munir, et al.Pageof 2